# Clinical Trial Landscape: 06_breast_her2_positive

*Generated: 2026-01-05 06:57:39*

## Summary

- **Total Trials**: 100
- **Flagged for Review**: 0
- **Search Terms Used**: 15

## Phase Distribution

| Phase | Count | Distribution |
|-------|-------|--------------|
| Phase 2 | 34 | ██████ 34.0% |
| Phase 1 | 21 | ████ 21.0% |
| Not Applicable | 13 | ██ 13.0% |
| Phase 1/Phase 2 | 12 | ██ 12.0% |
| Phase 3 | 10 | ██ 10.0% |
| Unknown | 6 | █ 6.0% |
| Early Phase 1 | 2 |  2.0% |
| Phase 2/Phase 3 | 1 |  1.0% |
| Phase 4 | 1 |  1.0% |

## Status Distribution

- **Recruiting**: 96 (96.0%)
- **Not yet recruiting**: 4 (4.0%)

## Top Sponsors

| Sponsor | Trial Count |
|---------|-------------|
| Washington University School of Medicine | 6 |
| Mayo Clinic | 5 |
| National Cancer Institute (NCI) | 4 |
| AstraZeneca | 4 |
| Abramson Cancer Center at Penn Medicine | 4 |
| Hoffmann-La Roche | 3 |
| M.D. Anderson Cancer Center | 2 |
| Laura Huppert, MD, BA | 2 |
| NRG Oncology | 2 |
| Emory University | 2 |
| University of Miami | 2 |
| Memorial Sloan Kettering Cancer Center | 2 |
| Dana-Farber Cancer Institute | 2 |
| National Institute of Diabetes and Digestive and K | 1 |
| Medical University of Vienna | 1 |

## Interventions

| Intervention | Occurrences |
|--------------|-------------|
| Biospecimen Collection | 8 |
| Questionnaire Administration | 7 |
| Pembrolizumab | 6 |
| Letrozole | 6 |
| Computed Tomography | 6 |
| Abemaciclib | 5 |
| Fulvestrant | 4 |
| Tamoxifen | 4 |
| Ribociclib | 4 |
| Magnetic Resonance Imaging | 4 |
| Goserelin | 3 |
| Anastrozole | 3 |
| Quality-of-Life Assessment | 3 |
| Carboplatin | 3 |
| Paclitaxel | 3 |
| Inavolisib | 3 |
| Echocardiography Test | 3 |
| Multigated Acquisition Scan | 3 |
| Positron Emission Tomography | 3 |
| Palbociclib | 3 |

## Geographic Distribution

| Country | Trial Count |
|---------|-------------|
| United States | 100 |
| Spain | 18 |
| South Korea | 16 |
| France | 14 |
| Australia | 14 |
| China | 14 |
| Germany | 11 |
| Italy | 11 |
| United Kingdom | 11 |
| Japan | 11 |
| Canada | 11 |
| Israel | 9 |
| Poland | 9 |
| Brazil | 7 |
| Belgium | 7 |

## Search Term Provenance

| Term | Source | Confidence |
|------|--------|------------|
| HER2 positive | manual | 1.0 |
| HER2positive | manual | 0.9 |
| HER2-positive | manual | 0.9 |
| ER positive | manual | 1.0 |
| ERpositive | manual | 0.9 |
| ER-positive | manual | 0.9 |
| PR negative | manual | 1.0 |
| PRnegative | manual | 0.9 |
| PR-negative | manual | 0.9 |
| breast cancer | manual | 1.0 |
| HER2 positive breast cancer | manual | 1.0 |
| ER positive breast cancer | manual | 1.0 |
| PR negative breast cancer | manual | 1.0 |
| metastatic breast cancer | llm | 0.8 |
| MBC | llm | 0.8 |

## All Trials

| NCT ID | Phase | Status | Sponsor | Title |
|--------|-------|--------|---------|-------|
| [NCT06224673](https://clinicaltrials.gov/study/NCT06224673) | Phase 2 | Not yet recruiting | Laura Huppert, MD, B... | Phase II Open-label Study of ARX788... |
| [NCT06348134](https://clinicaltrials.gov/study/NCT06348134) | Phase 2 | Not yet recruiting | University of Chicag... | Assessing the Efficacy and Safety o... |
| [NCT06671613](https://clinicaltrials.gov/study/NCT06671613) | Not Applicable | Recruiting | VA Office of Researc... | Evaluating the Impact of Intermitte... |
| [NCT05874193](https://clinicaltrials.gov/study/NCT05874193) | Phase 2 | Not yet recruiting | Cristiana Costa Chas... | A Collaborative Community Effort Us... |
| [NCT06525766](https://clinicaltrials.gov/study/NCT06525766) | Phase 2 | Recruiting | Mayo Clinic | Single Arm Pilot Trial of Adaptive ... |
| [NCT06308094](https://clinicaltrials.gov/study/NCT06308094) | Not Applicable | Recruiting | Johns Hopkins Univer... | 320-detector Computed Tomography to... |
| [NCT06385262](https://clinicaltrials.gov/study/NCT06385262) | Phase 2 | Recruiting | Duke University | Safety, Efficacy, and Tumor Immune ... |
| [NCT06671912](https://clinicaltrials.gov/study/NCT06671912) | Phase 3 | Recruiting | Alliance for Clinica... | LoTam: A Randomized, Phase III Clin... |
| [NCT06541847](https://clinicaltrials.gov/study/NCT06541847) | Phase 2 | Recruiting | Healx Limited | A Phase 2, Open-Label, Single Arm, ... |
| [NCT06374459](https://clinicaltrials.gov/study/NCT06374459) | Phase 1/Phase 2 | Recruiting | Washington Universit... | A Phase Ib/II Trial of Zunsemetinib... |
| [NCT06695845](https://clinicaltrials.gov/study/NCT06695845) | Phase 2 | Recruiting | Jazz Pharmaceuticals | A Phase 2, Open-label, Multicenter ... |
| [NCT06623110](https://clinicaltrials.gov/study/NCT06623110) | Phase 2 | Recruiting | Glenn J. Hanna | A Phase 2 Study of Intralesional RP... |
| [NCT06691035](https://clinicaltrials.gov/study/NCT06691035) | Phase 1 | Recruiting | H. Lee Moffitt Cance... | Immunologic Targeting of Native and... |
| [NCT06555744](https://clinicaltrials.gov/study/NCT06555744) | Phase 1 | Recruiting | Zymeworks BC Inc. | A Phase 1, Open-label, Multicenter ... |
| [NCT06450873](https://clinicaltrials.gov/study/NCT06450873) | Phase 2 | Recruiting | Mayo Clinic | A Phase 2 Pilot Window of Opportuni... |
| [NCT06551116](https://clinicaltrials.gov/study/NCT06551116) | N/A | Recruiting | Abramson Cancer Cent... | QuantifyHER: Quantitative Immunoflu... |
| [NCT06361940](https://clinicaltrials.gov/study/NCT06361940) | Phase 2 | Recruiting | Medical College of W... | Molecular Analyses to Predict Pathw... |
| [NCT05977036](https://clinicaltrials.gov/study/NCT05977036) | Not Applicable | Recruiting | Washington Universit... | BettER: Biomarker Driven Early Ther... |
| [NCT06366347](https://clinicaltrials.gov/study/NCT06366347) | Phase 2 | Recruiting | Dana-Farber Cancer I... | Phase 2, Randomized, Trial of Maint... |
| [NCT06274567](https://clinicaltrials.gov/study/NCT06274567) | Not Applicable | Recruiting | Massachusetts Genera... | Targeting Emotion Regulation in Bip... |
| [NCT05154487](https://clinicaltrials.gov/study/NCT05154487) | Phase 2 | Recruiting | GOG Foundation | Phase 2 Study of Alpelisib and Fulv... |
| [NCT06473597](https://clinicaltrials.gov/study/NCT06473597) | Phase 4 | Recruiting | Antonios Likourezos | A Comparison of Rimegepant Orally D... |
| [NCT06185751](https://clinicaltrials.gov/study/NCT06185751) | Phase 1 | Recruiting | Washington Universit... | Phase 1 Dose-Escalation and Dose-Ex... |
| [NCT06439693](https://clinicaltrials.gov/study/NCT06439693) | Phase 2 | Recruiting | Dana-Farber Cancer I... | A Single-Arm, Phase II Study of Seq... |
| [NCT06260033](https://clinicaltrials.gov/study/NCT06260033) | Phase 2 | Recruiting | City of Hope Medical... | A Phase II Trial of Stereotactic Bo... |
| [NCT06401889](https://clinicaltrials.gov/study/NCT06401889) | N/A | Recruiting | Mayo Clinic | Enhancing Skin Appearance and Quali... |
| [NCT06263543](https://clinicaltrials.gov/study/NCT06263543) | Phase 2 | Recruiting | Reshma L. Mahtani, D... | SERIES: SEquencing Sacituzumab Govi... |
| [NCT06078267](https://clinicaltrials.gov/study/NCT06078267) | Not Applicable | Not yet recruiting | Analog Device, Inc. | Feasibility and Efficacy Study of t... |
| [NCT05837455](https://clinicaltrials.gov/study/NCT05837455) | Phase 2 | Recruiting | Washington Universit... | NeoTAILOR: A Phase II Biomarker-dir... |
| [NCT06126276](https://clinicaltrials.gov/study/NCT06126276) | Phase 2 | Recruiting | National Cancer Inst... | A Randomized Trial of Neratinib, A ... |
| [NCT06249048](https://clinicaltrials.gov/study/NCT06249048) | Phase 1/Phase 2 | Recruiting | Strand Therapeutics ... | A Phase 1/2, Open-label, Multi-cent... |
| [NCT05916196](https://clinicaltrials.gov/study/NCT05916196) | Phase 2 | Recruiting | Abramson Cancer Cent... | [18F]FLUOROESTRADIOL (FES) PET/CT I... |
| [NCT06253871](https://clinicaltrials.gov/study/NCT06253871) | Phase 1 | Recruiting | Iambic Therapeutics,... | A Phase 1/1b Study of IAM1363 in Pa... |
| [NCT05892302](https://clinicaltrials.gov/study/NCT05892302) | Not Applicable | Recruiting | University of Texas ... | A Culturally Tailored Scalable Asth... |
| [NCT06257264](https://clinicaltrials.gov/study/NCT06257264) | Phase 1 | Recruiting | BeiGene | A Phase 1a/1b Study of BG-68501, a ... |
| [NCT05996107](https://clinicaltrials.gov/study/NCT05996107) | Phase 1 | Recruiting | University of Michig... | A Phase 1B Study of Ribociclib Admi... |
| [NCT06219941](https://clinicaltrials.gov/study/NCT06219941) | Phase 2 | Recruiting | AstraZeneca | A Phase II, Open-label, Multi-centr... |
| [NCT05870579](https://clinicaltrials.gov/study/NCT05870579) | Phase 1 | Recruiting | Novartis Pharmaceuti... | A Phase Ib Dose Finding Study Asses... |
| [NCT06084481](https://clinicaltrials.gov/study/NCT06084481) | Phase 1 | Recruiting | AbbVie | A Phase 1 Open-Label Study to Evalu... |
| [NCT05925803](https://clinicaltrials.gov/study/NCT05925803) | Phase 3 | Recruiting | AstraZeneca | A Multicenter, Randomized, Parallel... |
| [NCT06127979](https://clinicaltrials.gov/study/NCT06127979) | Not Applicable | Recruiting | Memorial Sloan Kette... | Differential Changes in Ki67 Betwee... |
| [NCT06055881](https://clinicaltrials.gov/study/NCT06055881) | Not Applicable | Recruiting | Mayo Clinic | Primary Breast Oligoprogressive Sit... |
| [NCT06028022](https://clinicaltrials.gov/study/NCT06028022) | Phase 2 | Recruiting | Mayo Clinic | Reishi Mushroom Extract for Fatigue... |
| [NCT06099769](https://clinicaltrials.gov/study/NCT06099769) | Phase 2 | Recruiting | Memorial Sloan Kette... | A RANDOMIZED, PHASE II STUDY OF ENZ... |
| [NCT05659797](https://clinicaltrials.gov/study/NCT05659797) | Early Phase 1 | Recruiting | Abramson Cancer Cent... | Pilot Study Evaluating the Uptake o... |
| [NCT05892718](https://clinicaltrials.gov/study/NCT05892718) | Phase 1 | Recruiting | FBD Biologics Limite... | A Phase 1, Open-label, Multi-center... |
| [NCT06087653](https://clinicaltrials.gov/study/NCT06087653) | Phase 1/Phase 2 | Recruiting | Starton Therapeutics... | A Protocol to Assess the Safety, Ef... |
| [NCT06062498](https://clinicaltrials.gov/study/NCT06062498) | Phase 2 | Recruiting | Northwestern Univers... | Randomized Phase II Study of Elaces... |
| [NCT05928806](https://clinicaltrials.gov/study/NCT05928806) | Phase 2 | Recruiting | Michael B. Atkins, M... | Phase 2 Advanced Renal Cell Cancer ... |
| [NCT05953337](https://clinicaltrials.gov/study/NCT05953337) | Not Applicable | Recruiting | ABK Biomedical | Radioembolization Oncology Trial Ut... |

*... and 50 more trials (see trials.csv for full list)*
